Category C—No reports describing the use of iloperidone in human pregnancy have been located. However, there is a risk of extrapyramidal and/ or withdrawal symptoms in the newborn with atypical antipsychotics if they are used in the 3rd trimester.
It is not known if iloperidone is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.
All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo; caution in elderly due to its strong α1 activity and orthostasis and associated fall risk
There are no dosage adjustments required
Mild-moderate impairment: No dosage adjustment necessary. Severe hepatic impairment: Use is not recommended.